Diverging prognostic impacts of hypoxic markers according to NSCLC histology

Lung Cancer

Volumn 72, Issue 3, 2011, Pages 294-302

  Andersen, Sigve ^a,b   Eilertsen, Marte ^a   Donnem, Tom ^a,b   Al Shibli, Khalid ^a,c   Al Saad, Samer ^a,b   Busund, Lill Tove ^a,b   Bremnes, Roy M ^a,b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^c NORDLAND HOSPITAL   (Norway)

Author keywords

CAIX; GLUT1; HIF1 ; HIF2 ; LDH5; NSCLC; Prognostic impact; Stroma

Indexed keywords

CARBONATE DEHYDRATASE IX; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; STROMA; STROMA CELL; TISSUE MICROARRAY; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANOXIA; ANTIGENS, NEOPLASM; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARBONIC ANHYDRASES; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; ISOENZYMES; L-LACTATE DEHYDROGENASE; LUNG NEOPLASMS; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79955475949     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.10.006     Document Type: Article

References (56)

1. Pouyssegur J., Dayan F., Mazure N.M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006, 441:437-443.
2. Semenza G.L., Wang G.L. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992, 12:5447-5454.
3. Ema M., Taya S., Yokotani N., Sogawa K., Matsuda Y., Fujii-Kuriyama Y. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci USA 1997, 94:4273-4278.
4. Gu Y.Z., Moran S.M., Hogenesch J.B., Wartman L., Bradfield C.A. Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit. HIF3alpha. Gene Exp 1998, 7:205-213.
5. Clerici C., Planes C. Gene regulation in the adaptive process to hypoxia in lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 2009, 296:L267-L274.
6. Heidbreder M., Frohlich F., Johren O., et al. Hypoxia rapidly activates HIF-3α mRNA expression. FASEB J 2003, 02-0963fje.
7. Li Q.F., Wang X.R., Yang Y.W., LIN H. Hypoxia upregulates hypoxia inducible factor (HIF)-3alpha expression in lung epithelial cells: characterization and comparison with HIF-1alpha. Cell Res 2006, 16:548-558.
8. Tian H., McKnight S.L., Russell D.W. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 1997, 11:72-82.
9. Liu Y.L., Yu J.M., Song X.R., Wang X.W., Xing L.G., Gao B.B. Regulation of the chemokine receptor CXCR4 and metastasis by hypoxia-inducible factor in non small cell lung cancer cell lines. Cancer Biol Ther 2006, 5:1320-1326.
10. Shyu K.G., Hsu F.L., Wang M.J., Wang B.W., Lin S. Hypoxia-inducible factor 1[alpha] regulates lung adenocarcinoma cell invasion. Exp Cell Res 2007, 313:1181-1191.
11. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
12. Chiche J., Ilc K., Laferriere J., Trottier E., Dayan F., Mazure N.M., et al. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res 2009, 69:358-368.
13. Brahimi-Horn M.C., Chiche J., Pouyssegur J. Hypoxia and cancer. J Mol Med 2007, 85:1301-1307.
14. Semenza G.L. Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin Cancer Biol 2009, 19:12-16.
15. Milosevic M., Fyles A., Hedley D., Hill R., et al. The human tumor microenvironment: invasive (needle) measurement of oxygen and interstitial fluid pressure. Semin Radiat Oncol 2004, 14:249-258.
16. Brown J.M. Tumor microenvironment and the response to anticancer therapy. Cancer Biol Ther 2002, 1:453-458.
17. Gray L.H., Conger A.D., Ebert M., Hornsey S., Scott O.C. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953, 26:638-648.
18. Vaupel P. Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. Oncologist 2008, 13(Suppl. 3):21-26.
19. Le Q.T., Chen E., Salim A., Cao H., Kong C.S., Whyte R., et al. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res 2006, 12:1507-1514.
20. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
21. Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007, 18:581-592.
22. West H., Harpole D., Travis W. Histologic considerations for individualized systemic therapy approaches for the management of non-small cell lung cancer. Chest 2009, 136:1112-1118.
23. Donnem T., Al-Saad S., Al-Shibli K., Delghandi M.P., Persson M., Nilsen M.N., et al. Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer. Clin Cancer Res 2007, 13:6649-6657.
24. Donnem T., Al-Saad S., Al-Shibli K., Andersen S., Busund L.T., Bremnes R.M. Prognostic impact of platelet-derived growth factors in non-small cell lung cancer tumor and stromal cells. J Thorac Oncol 2008, 3:963-970.
25. Gibbs A.R., Thunnissen F.B. Histological typing of lung and pleural tumours: third edition. J Clin Pathol 2001, 54:498-499.
26. Al-Shibli K.I., Donnem T., Al-Saad S., Persson M., Bremnes R.M., Busund L.T. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 2008, 14:5220-5227.
27. Giatromanolaki A., Koukourakis M.I., Sivridis E., Turley H., Talks K., Pezzella F., et al. Relation of hypoxia inducible factor 1[agr] and 2[agr] in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer 2001, 85:881-890.
28. Giatromanolaki A., Koukourakis M.I., Sivridis E., Turley H., Wykoff C.C., Gatter K.C., et al. DEC1 (STRA13) protein expression relates to hypoxia-inducible factor 1-alpha and carbonic anhydrase-9 overexpression in non-small cell lung cancer. J Pathol 2003, 200:222-228.
29. Kim S.J., Rabbani Z.N., Dewhirst M.W., Vujaskovic Z., Vollmer R.T., Schreiber E.G., et al. Expression of HIF-1[alpha], CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer 2005, 49:325-335.
30. Swinson D.E., Jones J.L., Richardson D., Wykoff C., Turley H., Pastorek J., et al. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol 2003, 21:473-482.
31. Semenza G.L., Jiang B.H., Leung S.W., Passantino R., Concodet J.P., Maire P., et al. Hypoxia response elements in the aldolase A. Enolase 1, and lactate dehydrogenase a gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 1996, 271:32529-32537.
32. Kaluz S., Kaluzovβ M., Liao S.Y., Lerman M., Stanbridge E.J. Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: a one transcription factor (HIF-1) show?. Biochim Biophys Acta (BBA) - Rev Cancer 2009, 1795:162-172.
33. Uchida T., Rossignol F., Matthay M.A., Mounier R., Couette S., Clottes E., et al. Prolonged hypoxia differentially regulates hypoxia-inducible factor (HIF)-1{alpha} and HIF-2{alpha} expression in lung epithelial cells: implication of natural antisense HIF-1{alpha}. J Biol Chem 2004, 279:14871-14878.
34. Ishibashi H., Nakagawa K., Onimaru M., Castellanous E.J., Kaneda Y., Nakashima Y., et al. Sp1 decoy transfected to carcinoma cells suppresses the expression of vascular endothelial growth factor, transforming growth factor beta1, and tissue factor and also cell growth and invasion activities. Cancer Res 2000, 60:6531-6536.
35. Pore N., Gupta A.K., Cerniglia G.J., Jiang Z., Bernhard E.J., Evans S.M., et al. Nelfinavir down-regulates hypoxia-inducible factor 1{alpha} and VEGF expression and increases tumor oxygenation: implications for radiotherapy. Cancer Res 2006, 66:9252-9259.
36. Lee C.H., Lee M.K., Kang C.D., Kim Y.D., Park D.Y., Kim J.Y., et al. Differential expression of hypoxia inducible factor-1 alpha and tumor cell proliferation between squamous cell carcinomas and adenocarcinomas among operable non-small cell lung carcinomas. J Korean Med Sci 2003, 18:196-203.
37. Ito T., Noguchi Y., Satoh S., Hayashi H., Inayama Y., Kitamura H. Expression of facilitative glucose transporter isoforms in lung carcinomas: its relation to histologic type, differentiation grade, and tumor stage. Mod Pathol 1998, 11:437-443.
38. Koukourakis M.I., Giatromanolaki A., Bougioukas G., Sivridis E. Lung cancer: a comparative study of metabolism related protein expression in cancer cells and tumor associated stroma. Cancer Biol Ther 2007, 6:1476-1479.
39. Younes M., Brown R.W., Stephenson M., Gondo M., Cagle P.T. Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 1997, 80:1046-1051.
40. Minami K., Saito Y., Imamura H., Okamura A. Prognostic significance of p53, Ki-67, VEGF and Glut-1 in resected stage I adenocarcinoma of the lung. Lung Cancer 2002, 38:51-57.
41. Nguyen X.C., Lee W.W., Chung J.H., Park S.Y., Sung S.W., KIM Y.K. FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: Correlations and prognostic values. Eur J Radiol 2007, 62:214-219.
42. Rastogi S., Banerjee S., Chellappan S., Simon G.R. Glut-1 antibodies induce growth arrest and apoptosis in human cancer cell lines. Cancer Lett 2007, 257:244-251.
43. Koukourakis M.I., Giatromanolaki A., Sivridis E., Bougioukas G., Didilis V., Gatter K.C., et al. Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer 2003, 89:877-885.
44. Giatromanolaki A., Koukourakis M.I., Sivridis E., Pastorek J., Wykoff C.C., Gatter K.C., et al. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 2001, 61:7992-7998.
45. Kim S.J., Rabbani Z.N., Vollmer R.T., Schreiber E.G., OOsterwijk E., Dewhirst M.W., et al. Carbonic anhydrase IX in early-stage non-small cell lung cancer. Clin Cancer Res 2004, 10:7925-7933.
46. Kon-no H., Ishii G., Nagai K., Yoshida J., Nishimura M., Nara M., et al. Carbonic anhydrase IX expression is associated with tumor progression and a poor prognosis of lung adenocarcinoma. Lung Cancer 2006, 54:409-418.
47. Nakao M., Ishii G., Nagai K., Kawase A., Kenmutso H., Kon-no H., et al. Prognostic significance of carbonic anhydrase IX expression by cancer-associated fibroblasts in lung adenocarcinoma. Cancer 2009, 115:2732-2743.
48. Pastorekova S., Parkkila S., Zavada J. Tumor-associated carbonic anhydrases and their clinical significance. Adv Clin Chem 2006, 42:167-216.
49. Gazdar A.F. Personalized medicine and inhibition of EGFR signaling in lung cancer. N Engl J Med 2009, 361:1018-1020.
50. Gandara D.R., Lara P.N., Mack P., Scagliotti G. Individualizing therapy for non-small-cell lung cancer: a paradigm shift from empiric to integrated decision-making. Clin Lung Cancer 2009, 10:148-150.
51. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
52. Scagliotti G., Hanna N., Fossella F., Sugarmark K., Blatter J., Peterson P., et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009, 14:253-263.
53. Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vanseenkiste J., Manegold C., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
54. Dikmen Z.G., Gellert G.C., Dogan P., Yoon H., Lee Y.B., Ahn C.H., et al. In vivo and in vitro effects of a HIF-1alpha inhibitor, RX-0047. J Cell Biochem 2008, 104:985-994.
55. Semenza G.L. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today 2007, 12:853-859.
56. Thiry A., Dogne J.M., Masereel B., Supuran C.T. Targeting tumor-associated carbonic anhydrase IX in cancer therapy. Trends Pharmacol Sci 2006, 27:566-573.